Silence Therapeutics plc(SLN)

$9.37—

Chart

Silence Therapeutics plc(SLN)

NASDAQ

$9.37—

Chart Studio

SLN(SLN)

SLN

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.14

Aug 6, 2026 · Reports before open

Revenue Estimate

$1M

Analyst Sentiment

Wall St. Consensus

Buy

5 analysts·Limited coverage

Score

4 Buy (80%)0 Hold (0%)1 Sell (20%)

Rating Breakdown

Strong Buy

00%

Buy

480%

Hold

00%

Sell

120%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$49.00

+423.2%

Consensus

$55.00

+487.3%

Bull

$67.00

+615.4%

12-Month Target Range5 analysts

$49.00$55.00$67.00

Current $9.37Consensus

Current Price

$9.37

Upside to Consensus

$45.63

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+37.92%

EPS—

FY2028

Rev+225.03%

EPS—

FY2029

Rev+380.36%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$3M	$5M	$15M	$72M	$170M
Low	$274,648	$242,752	$1M	$5M	$12M
High	$12M	$13M	$53M	$253M	$596M
EBITDA Avg	$-3M	$-5M	$-15M	$-72M	$-170M
Low	$-12M	$-13M	$-53M	$-253M	$-596M
High	$-274,648	$-242,752	$-1M	$-5M	$-12M
EBIT Avg	$-3M	$-5M	$-15M	$-72M	$-170M
Low	$-12M	$-13M	$-53M	$-253M	$-596M
High	$-274,648	$-242,752	$-1M	$-5M	$-12M
Net Income Avg	$-25M	$-30M	$-31M	$-30M	$-24M
Low	$-42M	$-35M	$-130M	$-126M	$-104M
High	$-11M	$-24M	$6M	$6M	$5M
EPS Avg	$-0.53	$-0.63	$-0.65	$-0.63	$-0.52
Low	$-0.89	$-0.74	$-2.76	$-2.66	$-2.20
High	$-0.23	$-0.50	$0.13	$0.13	$0.11
Analysts (Rev / EPS)	5 / 2	4 / 1	2 / 1	3 / 1	3 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$1M	$1M	$1M	$2M	$2M	$2M	$164,100	$155,900
Low	$66,459	$65,204	$81,717	$95,570	$95,452	$95,720	$9,559	$9,081
High	$2M	$2M	$3M	$3M	$3M	$3M	$318,640	$302,718
EBITDA Avg	$-1M	$-1M	$-1M	$-2M	$-2M	$-2M	$-164,100	$-155,900
Low	$-2M	$-2M	$-3M	$-3M	$-3M	$-3M	$-318,640	$-302,718
High	$-66,459	$-65,204	$-81,717	$-95,570	$-95,452	$-95,720	$-9,559	$-9,081
EBIT Avg	$-1M	$-1M	$-1M	$-2M	$-2M	$-2M	$-164,100	$-155,900
Low	$-2M	$-2M	$-3M	$-3M	$-3M	$-3M	$-318,640	$-302,718
High	$-66,459	$-65,204	$-81,717	$-95,570	$-95,452	$-95,720	$-9,559	$-9,081
Net Income Avg	$-6M	$-6M	$-7M	$-6M	$-7M	$-8M	$-5M	$-5M
Low	$-6M	$-14M	$-16M	$-14M	$-15M	$-18M	$-10M	$-10M
High	$-6M	$1M	$2M	$1M	$2M	$2M	$1M	$1M
EPS Avg	$-0.13	$-0.13	$-0.15	$-0.13	$-0.14	$-0.17	$-0.10	$-0.10
Low	$-0.13	$-0.29	$-0.34	$-0.30	$-0.32	$-0.38	$-0.22	$-0.22
High	$-0.12	$0.03	$0.03	$0.03	$0.03	$0.04	$0.02	$0.02
Analysts (Rev / EPS)	4 / 1	3 / 1	3 / 1	2 / 1	2 / 1	3 / 1	2 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Jun 28, 2024Chardan Capital

Silence Therapeutics price target raised to $55 from $42 at Chardan

Target:$55.00

+189.5%from $19.00

Jun 28, 2024Morgan Stanley

Silence Therapeutics price target raised to $49 from $45 at Morgan Stanley

Target:$49.00

+157.9%from $19.00

Mar 13, 2024BMO Capital

BMO Capital Reiterates Silence Therapeutics (SLN) as Top Pick, 'buy the dip'

Target:$67.00

+161.6%from $25.61

Dec 9, 2022Morgan Stanley

Morgan Stanley Initiates Coverage On Silence Therapeutics with Equal-Weight Rating, Announces Price Target of $18

Target:$18.00

+18.2%from $15.23

Nov 17, 2022Chardan Capital

Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $29

Target:$29.00

+119.5%from $13.21

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance